Background: Limited data exist examining the association between incident cancer and cumulative integrase inhibitor (INSTI) exposure. Methods: Participants were followed from baseline (latest of local cohort enrollment or January 1, 2012) until the earliest of first cancer, final follow-up, or December 31, 2019. Negative binomial regression was used to assess associations between cancer incidence and time-updated cumulative INSTI exposure, lagged by 6 months. Results: Of 29 340 individuals, 74% were male, 24% were antiretroviral treatment (ART)-naive, and median baseline age was 44 years (interquartile range [IQR], 36-51). Overall, 13 950 (48%) individuals started an INSTI during follow-up. During 160 657 person-years of follow-up ([PYFU] median 6.2; IQR, 3.9-7.5), there were 1078 cancers (incidence rate [IR] 6.7/1000 PYFU; 95% confidence interval [CI], 6.3-7.1). The commonest cancers were non-Hodgkin lymphoma (n=113), lung cancer (112), Kaposi's sarcoma (106), and anal cancer (103). After adjusting for potential confounders, there was no association between cancer risk and INSTI exposure (≤6 months vs no exposure IR ratio: 1.15 [95% CI, 0.89-1.49], >6-12 months; 0.97 [95% CI, 0.71-1.32], >12-24 months; 0.84 [95% CI, 0.64-1.11], >24-36 months; 1.10 [95% CI, 0.82-1.47], >36 months; 0.90 [95% CI, 0.65-1.26] [P=.60]). In ART-naive participants, cancer incidence decreased with increasing INSTI exposure, mainly driven by a decreasing incidence of acquired immune deficiency syndrome cancers; however, there was no association between INSTI exposure and cancer for those ART-experienced (interaction P<.0001). Conclusions: Cancer incidence in each INSTI exposure group was similar, despite relatively wide CIs, providing reassuring early findings that increasing INSTI exposure is unlikely to be associated with an increased cancer risk, although longer follow-up is needed to confirm this finding.

Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting / Greenberg, L.; Ryom, L.; Neesgaard, B.; Miro, J. M.; Dahlerup Rasmussen, L.; Zangerle, R.; Grabmeier-Pfistershammer, K.; Gunthard, H. F.; Kusejko, K.; Smith, C.; Mussini, C.; Menozzi, M.; Wit, F.; Van Der Valk, M.; D'Arminio Monforte, A.; De Wit, S.; Necsoi, C.; Pelchen-Matthews, A.; Lundgren, J.; Peters, L.; Castagna, A.; Muccini, C.; Vehreschild, J. J.; Pradier, C.; Bruguera Riera, A.; Sonnerborg, A.; Petoumenos, K.; Garges, H.; Rogatto, F.; Dedes, N.; Bansi-Matharu, L.; Mocroft, A.. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 9:3(2022), pp. 1-11. [10.1093/ofid/ofac029]

Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting

Mussini C.;Menozzi M.;
2022

Abstract

Background: Limited data exist examining the association between incident cancer and cumulative integrase inhibitor (INSTI) exposure. Methods: Participants were followed from baseline (latest of local cohort enrollment or January 1, 2012) until the earliest of first cancer, final follow-up, or December 31, 2019. Negative binomial regression was used to assess associations between cancer incidence and time-updated cumulative INSTI exposure, lagged by 6 months. Results: Of 29 340 individuals, 74% were male, 24% were antiretroviral treatment (ART)-naive, and median baseline age was 44 years (interquartile range [IQR], 36-51). Overall, 13 950 (48%) individuals started an INSTI during follow-up. During 160 657 person-years of follow-up ([PYFU] median 6.2; IQR, 3.9-7.5), there were 1078 cancers (incidence rate [IR] 6.7/1000 PYFU; 95% confidence interval [CI], 6.3-7.1). The commonest cancers were non-Hodgkin lymphoma (n=113), lung cancer (112), Kaposi's sarcoma (106), and anal cancer (103). After adjusting for potential confounders, there was no association between cancer risk and INSTI exposure (≤6 months vs no exposure IR ratio: 1.15 [95% CI, 0.89-1.49], >6-12 months; 0.97 [95% CI, 0.71-1.32], >12-24 months; 0.84 [95% CI, 0.64-1.11], >24-36 months; 1.10 [95% CI, 0.82-1.47], >36 months; 0.90 [95% CI, 0.65-1.26] [P=.60]). In ART-naive participants, cancer incidence decreased with increasing INSTI exposure, mainly driven by a decreasing incidence of acquired immune deficiency syndrome cancers; however, there was no association between INSTI exposure and cancer for those ART-experienced (interaction P<.0001). Conclusions: Cancer incidence in each INSTI exposure group was similar, despite relatively wide CIs, providing reassuring early findings that increasing INSTI exposure is unlikely to be associated with an increased cancer risk, although longer follow-up is needed to confirm this finding.
2022
9
3
1
11
Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting / Greenberg, L.; Ryom, L.; Neesgaard, B.; Miro, J. M.; Dahlerup Rasmussen, L.; Zangerle, R.; Grabmeier-Pfistershammer, K.; Gunthard, H. F.; Kusejko, K.; Smith, C.; Mussini, C.; Menozzi, M.; Wit, F.; Van Der Valk, M.; D'Arminio Monforte, A.; De Wit, S.; Necsoi, C.; Pelchen-Matthews, A.; Lundgren, J.; Peters, L.; Castagna, A.; Muccini, C.; Vehreschild, J. J.; Pradier, C.; Bruguera Riera, A.; Sonnerborg, A.; Petoumenos, K.; Garges, H.; Rogatto, F.; Dedes, N.; Bansi-Matharu, L.; Mocroft, A.. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 9:3(2022), pp. 1-11. [10.1093/ofid/ofac029]
Greenberg, L.; Ryom, L.; Neesgaard, B.; Miro, J. M.; Dahlerup Rasmussen, L.; Zangerle, R.; Grabmeier-Pfistershammer, K.; Gunthard, H. F.; Kusejko, K.; Smith, C.; Mussini, C.; Menozzi, M.; Wit, F.; Van Der Valk, M.; D'Arminio Monforte, A.; De Wit, S.; Necsoi, C.; Pelchen-Matthews, A.; Lundgren, J.; Peters, L.; Castagna, A.; Muccini, C.; Vehreschild, J. J.; Pradier, C.; Bruguera Riera, A.; Sonnerborg, A.; Petoumenos, K.; Garges, H.; Rogatto, F.; Dedes, N.; Bansi-Matharu, L.; Mocroft, A.
File in questo prodotto:
File Dimensione Formato  
ofac029.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 383.57 kB
Formato Adobe PDF
383.57 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1271443
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact